Abstract
Relapsing polychondritis (RP) is a rare immune-mediated disease of unknown origin that causes recurrent cartilage inflammation. Its peak incidence is in the 4th or 5th decade of life with a female to male ratio of 3:1. Whereas auricular cartilaginous inflammation is the most common presentation, relapsing polychondritis can also involve cartilaginous components of the respiratory tract, joints, heart, and blood vessels. Corticosteroids are the first line of treatment. Immunosuppressants such as cyclosporine, azathioprine, methotrexate, and cyclophosphamide are possible alternatives. Additionally, the biologic agent antiCD20 monoclonal antibody (rituximab) has been found to be helpful in treating RP. [1] Abdwani R. Kolethekkat A.A. Al Abri R. Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): first case report. Int J Pediatr Otorhinolaryngol. 2012; 76: 1061-1064 Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
